Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02861014
Recruitment Status : Completed
First Posted : August 10, 2016
Results First Posted : February 3, 2021
Last Update Posted : February 3, 2021
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this prospective, multicenter, open-label, efficacy, and safety study is to assess the efficacy and safety of ocrelizumab in participants with Relapsing Remitting Multiple Sclerosis (RRMS) who have had a suboptimal response to an adequate course of a Disease-Modifying Treatment (DMT). The study will consist of a Screening period (up to 4 weeks), an Open-label treatment period (96 weeks; with last dose administered at Week 72), and a Follow-up period of at least 2 years.

Condition or disease Intervention/treatment Phase
Multiple Sclerosis, Relapsing-Remitting Biological: Ocrelizumab Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 681 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Study To Evaluate the Efficacy and Safety of Ocrelizumab in Patients With Relapsing Multiple Sclerosis Who Have A Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Actual Study Start Date : September 9, 2016
Actual Primary Completion Date : October 25, 2019
Actual Study Completion Date : December 15, 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Ocrelizumab

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Ocrelizumab
Ocrelizumab will be administered as two 300 mg IV infusions on Days 1 and 15 followed by one 600 mg IV infusions administered at Weeks 24, 48, and 72.
 Biological: Ocrelizumab
Ocrelizumab will be administered as two 300 mg IV infusions on Days 1 and 15 followed by one 600 mg IV infusions administered at Weeks 24, 48, and 72.
Other Name: RO4964913


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Percentage of Participants With No Evidence of Disease Activity (NEDA) as Per Protocol Defined Events During a 96-Week Period [ Time Frame: Week 96 ]

    A protocol-defined event of disease activity was defined by the occurrence of at least one of the following while on treatment with ocrelizumab:

    • A protocol-defined relapse (PDR)
    • 24-week CDP based on increase in EDSS while on treatment with ocrelizumab
    • A T1 Gd-enhanced lesion after Week 8
    • A new and/or enlarging T2 hyperintense lesion on MRI after Week 8 compared to the Week 8 MRI scan


Secondary Outcome Measures :
  1. Percentage of Participants Free From a Protocol-Defined Event of Disease Activity During 24 Weeks Period [ Time Frame: Baseline up to 24 weeks ]

    A protocol-defined event of disease activity was defined by the occurrence of at least one of the following while on treatment with ocrelizumab:

    • A protocol-defined relapse (PDR)
    • 24-week CDP based on increase in EDSS while on treatment with ocrelizumab
    • A T1 Gd-enhanced lesion after Week 8
    • A new and/or enlarging T2 hyperintense lesion on MRI after Week 8 compared to the Week 8 MRI scan

  2. Percentage of Participants Free From a Protocol-Defined Event of Disease Activity During 48 Weeks Period [ Time Frame: Baseline up to 48 weeks ]

    A protocol-defined event of disease activity was defined by the occurrence of at least one of the following while on treatment with ocrelizumab:

    • A protocol-defined relapse (PDR)
    • 24-week CDP based on increase in EDSS while on treatment with ocrelizumab
    • A T1 Gd-enhanced lesion after Week 8
    • A new and/or enlarging T2 hyperintense lesion on MRI after Week 8 compared to the Week 8 MRI scan

  3. Time to First Protocol-Defined Event of Disease Activity [ Time Frame: Baseline up to 96 Weeks ]

    The definition of a protocol-defined event of disease activity is the occurrence of at least one of the following while on treatment with ocrelizumab:

    • A protocol-defined relapse defined as: Symptoms must persist for >24 hours and should not be attributable to confounding clinical factors; Symptoms should be preceded by neurological stability for at least 30 days; Symptoms should be accompanied by new objective neurological worsening determined with a timely EDSS/ Functional Systems Score (FSS) assessment
    • 24 weeks confirmed disability progression based on increases in EDSS while on treatment with ocrelizumab
    • A T1 Gd-enhanced lesion after Week 8
    • A new and/or enlarging T2 hyperintense lesion on MRI after Week 8 compared to the Week 8 MRI scan.

  4. Change From Baseline to Week 96 in Expanded Disability Status Scale (EDSS) [ Time Frame: Baseline, Weeks: 24, 48, 72, 96 ]
    The EDSS is an ordinal clinical rating scale ranging from 0 (normal neurologic examination) to 10 (death due to MS) in half-point increments.

  5. Absolute Change From Baseline in EDSS Category at Week 96 [ Time Frame: Up to Week 96 ]
    The EDSS is an ordinal clinical rating scale ranging from 0 (normal neurologic examination) to 10 (death due to MS) in half-point increments.

  6. Percentage of Participants With a Baseline EDSS Score ≥2 With CDI at Week 96 [ Time Frame: Week 96 ]
    The EDSS is an ordinal clinical rating scale ranging from 0 (normal neurologic examination) to 10 (death due to MS) in half-point increments.

  7. Annualized Protocol-defined Relapse Rate at Week 96 [ Time Frame: Week 96 ]
  8. Time to Onset of 24-week Confirmed Disability Progression [ Time Frame: Baseline up to 96 Weeks ]
  9. Time to Onset of First Protocol-Defined Relapse [ Time Frame: Baseline up to 96 Weeks ]

    A protocol-defined multiple sclerosis (MS) relapse is an occurrence of new or worsening neurological symptoms attributable to MS that meets the following criteria:

    • Symptoms must persist for >24 hours and should not be attributable to confounding clinical factors (e.g., fever, infection, injury, adverse reactions to medications)
    • Symptoms should be preceded by neurological stability for at least 30 days

    • Symptoms should be accompanied by new objective neurological worsening determined with a timely EDSS/ Functional Systems Score (FSS) assessment, consistent with an increase of at least:

      • ≥ 0.5 points on EDSS scale
      • or ≥ 2 points on one of the following FSS scales: pyramidal, ambulation, cerebellar, brainstem, sensory, or visual
      • or ≥ 1 point on two or more of the following FSS scales: pyramidal, ambulation, cerebellar, brainstem, sensory, or visual

  10. Time to Onset of First New and/or Enlarging T2 Lesion [ Time Frame: Baseline up to 96 Weeks ]
  11. Mean Number of T1 Gd-enhancing Lesions Per MRI Scan at Weeks 24, 48 and 96 [ Time Frame: Weeks: 24, 48, 96 ]
    Mean number of T1 Gd-enhancing lesions per MRI scan: Total number of T1 Gd-enhanced lesions divided by the total number of interpretable MRI scans

  12. Change From Baseline to Week 96 in Total T2 Lesion Volume Detected by Brain MRI From [ Time Frame: Baseline, Week 96 ]
  13. Percentage Change From Baseline to Week 96 in Total T2 Lesion Volume Detected by Brain MRI [ Time Frame: Baseline, Week 96 ]
  14. Volume of New and/or Enlarging T2 Hyperintense Lesions Volume of Lesions Per MRI Scan at Weeks 24, 48, 96 [ Time Frame: Weeks 24, 48, 96 ]
    The number of new and/or enlarging T2 lesions at week 24, 48 and 96 is calculated as the sum of the individual number of new and/or enlarging lesions at each visit. Data from other unscheduled assessments is included in this summary or analysis.

  15. Mean Number of New and/or Enlarging T2 Hyperintense Lesions Per MRI Scan [ Time Frame: Weeks 24, 48, 96 ]
    Mean number of new and/or enlarging T2 hyperintense lesions per MRI scan: Total number of new and/or enlarging T2 hyperintense lesions divided by the total number of interpretable MRI scans

  16. Change From Baseline at Week 48 and 96 in T1 Hypointense Lesion Volume [ Time Frame: Weeks 48, 96 ]
  17. Percentage Change From Baseline at Week 48 and 96 in T1 Hypointense Lesion Volume [ Time Frame: Weeks 48, 96 ]
  18. Adjusted Mean Change From Baseline at Week 48 and 96 in T1 Hypointense Lesion Volume [ Time Frame: Weeks 48, 96 ]
  19. Adjusted Mean Percentage Change From Baseline in Brain Volume [ Time Frame: Weeks 24, 48, 96 ]
  20. Adjusted Mean Percentage Change From Baseline in Cortical Grey Matter Volume [ Time Frame: Weeks 48, 96 ]
  21. Adjusted Mean Percentage Change From Baseline in White Matter Volume [ Time Frame: Weeks 48, 96 ]
  22. Mean Change From Baseline in Cognitive Performance (Processing Speed/Working Memory) at Week 48 and Week 96 as Measured by the Brief International Cognitive Assessment for MS - Symbol Digit Modalities Test (SDMT) Score [ Time Frame: Baseline, Weeks: 48, 96 ]
    Brief International Cognitive Assessment for MS (BICAMS) is assessing cognitive processing speed and verbal and visual memory. Symbol Digits Modalities Test (SDMT) is assessing processing speed/working memory. The SDMT presents a series of nine symbols, each paired with a single digit in a key at the top of a standard sheet of paper. Participants are asked to voice the digit associated with each symbol as rapidly as possible for 90 sec. There is a single outcome measure - the number correct over the 90 sec time span. The higher the results, the better processing speed/working memory.

  23. Change From Baseline in Cognitive Performance (Visuospatial Memory) at Week 48 and Week 96 as Measured by the Brief International Cognitive Assessment for MS - Brief Visuospatial Memory Test-Revised (BVMT-R) Score [ Time Frame: Baseline, Weeks 48, 96 ]
    Brief International Cognitive Assessment for MS (BICAMS) is assessing cognitive processing speed and verbal and visual memory. Brief Visuospatial Memory Test-Revised (BVMT-R) is assessing visuospatial memory. In this test, six abstract designs are presented for 10 sec. The display is removed from view and patients render the stimuli via pencil on paper manual responses. Each design receives from 0 to 2 points representing accuracy and location. There are three learning trials, and the outcome measure is the total number of points earned over the three learning trials, thus the scale range is 0-36. The higher the result, the better visual/spatial memory.

  24. Percentage Change From Baseline in Cognitive Performance (Processing Speed/Working Memory) at Week 48 and Week 96 as Measured by the Brief International Cognitive Assessment for MS - Symbol Digit Modalities Test (SDMT) Score [ Time Frame: Baseline, Weeks 48, 96 ]
    Brief International Cognitive Assessment for MS (BICAMS) is assessing cognitive processing speed and verbal and visual memory. Symbol Digits Modalities Test (SDMT) is assessing processing speed/working memory. The SDMT presents a series of nine symbols, each paired with a single digit in a key at the top of a standard sheet of paper. Participants are asked to voice the digit associated with each symbol as rapidly as possible for 90 sec. There is a single outcome measure - the number correct over the 90 sec time span.

  25. Percentage Change From Baseline in Cognitive Performance (Visuospatial Memory) at Week 48 and Week 96 as Measured by the Brief International Cognitive Assessment for MS - Brief Visuospatial Memory Test-Revised (BVMT-R) Score [ Time Frame: Baseline, Weeks: 48, 96 ]
    Brief International Cognitive Assessment for MS (BICAMS) is assessing cognitive processing speed and verbal and visual memory. Brief Visuospatial Memory Test-Revised (BVMT-R) is assessing visuospatial memory. In this test, six abstract designs are presented for 10 sec. The display is removed from view and patients render the stimuli via pencil on paper manual responses. Each design receives from 0 to 2 points representing accuracy and location. There are three learning trials, and the outcome measure is the total number of points earned over the three learning trials, thus the scale range is 0-36. The higher the result, the better visual/spatial memory.

  26. Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Baseline up to to 96 weeks after the end of the Treatment Period ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have a definite diagnosis of RRMS, confirmed as per the revised McDonald 2010 criteria
  • Have a length of disease duration, from first symptom, of less than (<) 10 years
  • Have received no more than two prior DMTs, and the discontinuation of the most recent DMT was due to lack of efficacy
  • Suboptimal disease control while on a DMT
  • Expanded Disability Status Scale (EDSS) of 0.0 to 4.0, inclusive, at Screening
  • For women of childbearing potential: agreement to use an acceptable birth control method during the treatment period and for at least 6 months after the last dose of study drug

Exclusion Criteria:

  • Secondary progressive multiple sclerosis (SPMS) or history of primary progressive or progressive relapsing multiple sclerosis (MS)
  • Inability to complete an Magnetic Resonance Imaging (MRI) procedure
  • Known presence of other neurological disorders
  • Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study
  • History or currently active primary or secondary immunodeficiency
  • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
  • History of opportunistic infections
  • History or known presence of recurrent or chronic infection
  • History of malignancy
  • Congestive heart failure
  • Known active bacterial, viral, fungal, mycobacterial infection or other infection, excluding fungal infection of nail beds
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02861014


Locations
Show Show 163 study locations
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-La Roche
  Study Documents (Full-Text)

Documents provided by Hoffmann-La Roche:
Study Protocol  [PDF] November 4, 2018
Statistical Analysis Plan  [PDF] December 16, 2019

More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT02861014    
Other Study ID Numbers: MA30005
2015-005597-38 ( EudraCT Number )
First Posted: August 10, 2016    Key Record Dates
Results First Posted: February 3, 2021
Last Update Posted: February 3, 2021
Last Verified: January 2021
Additional relevant MeSH terms:
Layout table for MeSH terms
Ocrelizumab
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
 Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Immunologic Factors
Physiological Effects of Drugs